new retatrutide Trial of next-gen weight-loss drug brings it one step closer to FDA approval Retatrutide clinical trial done! Now

"Important update: required documentation for select ePA requests." Confirms GLP-1 medications require attached documentation for ePA

SEMA treated mice showed tumor onset and progression at intermediate levels compared to RETA and Veh (Fig

Milne I, Lindner D, Bayer M, Husmeier D, McGuire G, Marshall DF, et al

Advances in metabolic medicine have introduced GLP-1 receptor agonists a doctor-supervised therapy designed to address the biological drivers of weight gain

Compounded versions are often used when the originals are in short supply or when a more affordable, individualized option is needed without compromising results

First, we must consider the adverse abdominal effects of GLP-1RA, which include nausea, abdominal distention, constipation, and diarrhea 41,42